Patient Search

KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story

https://momentum.vicc.org/2022/04/cancer-gave-me-clarity/

If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story.

https://momentum.vicc.org/2022/04/brighter-outlook/

Filter By:
Search by Keyword:

Displaying 11 - 20 of 23

A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors

Multiple Cancer Types

The purpose of this study is to evaluate the safety and tolerability of AB521 when taken
alone in participants with advanced solid tumor malignancies and clear cell renal cell
carcinoma (ccRCC).

Disease Sites: Kidney (Renal Cell), Phase I

Phase: I

Investigator: Rini, Brian

NCTID: NCT05536141

Protocol No: VICC-DTURO23168P

Learn More

A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms

Leukemia

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity
(DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion
(RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.

Disease Sites: Leukemia

Phase: I

Investigator: Savona, Michael

NCTID: NCT06034002

Protocol No: VICC-DTHEM23416P

Learn More

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Phase I

This is a Phase 1/2, open-label, non-randomized, 4-part Phase 1 trial to determine the safety
profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)
of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint
inhibitor (CPI) pembrolizumab (Keytruda).

Disease Sites: Phase I

Phase: I

Investigator: Davis, Elizabeth

NCTID: NCT04198766

Protocol No: VICCPHI2135

Learn More

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Multiple Cancer Types

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination
with talquetamab or teclistamab, and to characterize the safety and tolerability of
talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.

Disease Sites: Multiple Myeloma, Phase I

Phase: I

Investigator: Baljevic, Muhamed

NCTID: NCT05338775

Protocol No: VICCHEMP2253

Learn More

RBS2418 Evaluation in Subjects With Unresectable or Metastatic Tumors

Phase I

RBS2418 (investigational product) is a specific immune modulator, working through
ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor
immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine
monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine
production in the tumors. RBS2418 has the potential to be an important therapeutic option for
subjects both as monotherapy and in combination with checkpoint blockade. This study is an
open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in
combination with pembrolizumab or as a monotherapy in subjects with advanced unresectable,
recurrent or metastatic tumors.

Disease Sites: Phase I

Phase: I

Investigator: Berlin, Jordan

NCTID: NCT05270213

Protocol No: VICCPHI2289

Learn More

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Multiple Cancer Types

This Phase 1, multicenter, open-label, dose escalation study is designed to assess the
safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical
activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects
with advanced hematologic malignancies.

Disease Sites: Leukemia, Myelodysplastic Syndrome, Phase I

Phase: I

Investigator: Kishtagari, Ashwin

NCTID: NCT04891757

Protocol No: VICCHEMP2138

Learn More

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Multiple Cancer Types

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity
of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after
lymphodepletion consisting of cyclophosphamide and fludarabine.

Disease Sites: Lymphoma, Phase I

Phase: I

Investigator: Oluwole, Olalekan

NCTID: NCT04637763

Protocol No: VICC-DTCTT23155P

Learn More

A Phase I/Ib Study Evaluating Single-Agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Multiple Cancer Types

Disease Sites: Head/Neck, Phase I

Phase: I

Investigator: Choe, Jennifer

NCTID:

Protocol No: VICCHNP22118

Learn More

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of VGA039 Following Intravenous or Subcutaneous Administration of Single Ascending Doses in Healthy Adults and
Adult Patients with von Willebrand Disease

Disease Sites: Not Available

Phase: I

Investigator: Wheeler, Allison

NCTID: NCT05776069

Protocol No: NCBH2304-VEGA

Learn More

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients with Head and Neck Cancer

Phase I

This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography (SPECT)/computed tomography (CT) and panitumumab-IRDye800 fluorescence imaging during surgery (intraoperative), to detect disease in patients with head and neck cancer. 111In-panitumumab is an imaging agent made of a monoclonal antibody that has been labeled with a radioactive molecule called indium In 111. The agent targets and binds to receptors on tumor cells. This allows the cells to be visualized and assessed with SPECT/CT imaging techniques. SPECT is special type of CT scan in which a small amount of a radioactive drug is injected into a vein and a scanner is used to make detailed images of areas inside the body where the radioactive material is taken up by the cells. CT is an imaging technique for examining structures within the body by scanning them with x-rays and using a computer to construct a series of cross-sectional scans along a single axis. Panitumumab-IRDye800 is an imaging agent composed of panitumumab, a monoclonal antibody, linked to a fluorescent dye called IRDye800. Upon administration, panitumumab-IRDye800 targets and binds to receptors on tumor cells. This allows the tumor cells to be detected using fluorescence imaging during surgery. Adding 111In-panitumumab SPECT/CT imaging to intraoperative panitumumab-IRDye800 fluorescence imaging may be more effective at detecting disease in patients with head and neck cancer.

Disease Sites: Phase I

Phase: I

Investigator: Rosenthal, Eben

NCTID: NCT05945875

Protocol No: VICC-EDHAN23204P

Learn More